US · Healthcare · Biotechnology
EPS came in at -0.94 against a street estimate of -0.79 — a miss of 19.0%.
Analysts rate Spyre Therapeutics Inc. a strong buy (17 buy, 1 hold, 0 sell out of 18) with an average price target of $122.53.
| Fund | Stake |
|---|---|
| FMR Inc | 13.94% |
| BlackRock Inc | 6.96% |
| Perceptive Advisors LLC | 4.62% |
| RTW INVESTMENTS, LLC | 4.55% |
| Paradigm Biocapital Advisors LP | 4.11% |
| Vanguard Capital Management, LLC | 3.69% |
| State Street Corp | 3.27% |
| VR Adviser, LLC | 3.19% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Spyre reported a net loss of $96.121 million for Q3 2026, compared with $11.183 million in Q3 2025. • For the first nine months o | 2026-11-03 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 net loss was $96.1 million, compared with $11.2 million in the third quarter of 2025. • Third-quarter 2026 ope | 2026-11-03 |
| Material agreement · Q4 2026 HEADLINE NUMBERS • Spyre Therapeutics agreed to sell 4,117,648 shares of common stock at $85.00 per share. • Expected gross proceeds are approximate | 2026-10-07 |
| Reg FD disclosure · Q3 2026 SPYRE THERAPEUTICS, INC. - DOCUMENT SUMMARY HEADLINE NUMBERS • SPY003 Primary Endpoint Met: 10.0-point reduction in Robarts Histopathology Index (RH | 2026-09-08 |
| Reg FD disclosure · Q3 2026 SPYRE THERAPEUTICS, INC. – DOCUMENT SUMMARY HEADLINE NUMBERS • SPY072 Low Dose: -1.9 point change in DAS28-CRP at Week 12 (statistically significant | 2026-08-25 |
| Quarterly report · Q2 2026 SPYRE THERAPEUTICS, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and marketable securities: $1,145.3 million as of June 30, 2026 (up from $75 | 2026-08-04 |
| Results announced · Q3 2026 SPYRE THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position of $1,145.3 million ($162.0 million cash + $983.3 million mark | 2026-08-04 |
| Reg FD disclosure · Q2 2026 SPYRE THERAPEUTICS, INC. – FORM 8-K SUMMARY Date of Report: June 15, 2026 --- HEADLINE NUMBERS • Primary Endpoint Met: SPY002 achieved a statistica | 2026-06-15 |
Readable in the app.
| Announcement | Date |
|---|---|
| Expanded license agreement field of use with Paragon Therapeutics Spyre Therapeutics expanded the commercial rights to its SPY003 drug candidate on May 29, 2026. Originally limited to inflammatory bowel disease (IBD), the company can now pursue SPY003 in a | 2026-06-01 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Spyre Therapeutics Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.